keyword
MENU ▼
Read by QxMD icon Read
search

cancer associated venous thromboembolic disease

keyword
https://www.readbyqxmd.com/read/27913480/thrombosis-in-the-setting-of-cancer
#1
Michael B Streiff
Venous thromboembolism (VTE) is a common cause of adverse outcomes in patients with cancer. The risk of VTE varies with cancer type, stage and grade, cancer therapy, and supportive care, as well as patient characteristics including age, ethnicity, and inherited and acquired comorbid conditions. VTE prophylaxis should be provided to all hospitalized cancer patients and high-risk outpatients. Low-molecular-weight heparin (LMWH) remains the first-line therapy for VTE in patients with active cancer. Anticoagulation should be continued as long as there is evidence of active disease or patients are receiving cancer treatment...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27913214/alk-rearranged-non-small-cell-lung-cancer-is-associated-with-a-high-rate-of-venous-thromboembolism
#2
Alona Zer, Mor Moskovitz, David M Hwang, Anat Hershko-Klement, Ludmila Fridel, Grzegorz J Korpanty, Elizabeth Dudnik, Nir Peled, Tzippy Shochat, Natasha B Leighl, Geoffrey Liu, Ronald Feld, Ronald Burkes, Mira Wollner, Ming-Sound Tsao, Frances A Shepherd
BACKGROUND: Patients with lung cancer are at increased risk for venous thromboembolism (VTE), particularly those receiving chemotherapy. It is estimated that 8% to 15% of patients with advanced non-small-cell lung cancer (NSCLC) experience a VTE in the course of their disease. The incidence in patients with specific molecular subtypes of NSCLC is unknown. We undertook this review to determine the incidence of VTE in patients with ALK (anaplastic lymphoma kinase)-rearranged NSCLC. PATIENTS AND METHODS: We identified all patients with ALK-rearranged NSCLC diagnosed and/or treated at the Princess Margaret Cancer Centre (PM CC) in Canada between July 2012 and January 2015...
October 26, 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/27895794/trousseau-s-syndrome-caused-by-bladder-cancer-producing-granulocyte-colony-stimulating-factor-and-parathyroid-hormone-related-protein-a-case-report
#3
Tomonori Kato, Kenji Yasuda, Hiroaki Iida, Akihiko Watanabe, Yasuyoshi Fujiuchi, Shigeharu Miwa, Johji Imura, Akira Komiya
The present study reports a rare case of bladder cancer that caused Trousseau's syndrome, a malignancy-associated hypercoagulative state leading to venous or arterial thrombosis. A 38-year-old Japanese female patient experienced a sudden onset of visual field defects and lower limb weakness. Cerebral magnetic resonance imaging revealed multi-regional hypointense areas compatible with acute cerebral infarction. Despite the repeated administration of anticoagulant treatment with heparin, the condition could not be adequately controlled and thromboembolic events occasionally recurred...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27882374/cancer-associated-venous-thromboembolism-burden-mechanisms-and-management
#4
Cihan Ay, Ingrid Pabinger, Alexander T Cohen
Venous thromboembolism (VTE) is a significant health problem in the general population but especially in cancer patients. In this review, we discuss the epidemiology and burden of the disease, the pathophysiology of cancer-associated VTE, and the clinical treatment options for both primary prevention and acute treatment. Overall, the development of VTE in cancer patients is related to increases in morbidity, mortality, and medical costs. However, the incidence of cancer-associated VTE varies due to patient-related factors (e...
November 24, 2016: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/27869893/-anmco-position-paper-recommendations-for-the-follow-up-of-patients-with-pulmonary-thromboembolism
#5
Carlo D'Agostino, Pietro Zonzin, Iolanda Enea, Michele Massimo Gulizia, Walter Ageno, Piergiuseppe Agostoni, Michele Azzarito, Cecilia Becattini, Amedeo Bongarzoni, Francesca Bux, Franco Casazza, Nicoletta Corrieri, Michele D'Alto, Nicola D'Amato, Andrea Maria D'Armini, Maria Grazia De Natale, Giovanni Di Minno, Giuseppe Favretto, Lucia Filippi, Valentina Grazioli, Gualtiero Palareti, Raffaele Pesavento, Loris Roncon, Laura Scelsi, Antonella Tufano
Venous thromboembolism (VTE), including deep venous thrombosis and pulmonary embolism, is the third most common cause of cardiovascular death. The management of the acute phase of VTE is well described in several papers and guidelines, whereas the management of the follow-up of the patients affected from VTE is less defined. This position paper of the Italian Association of Hospital Cardiologists (ANMCO) tries to fill the gap using currently available evidence and the opinion of the experts to suggest the most useful way to manage patients in the chronic phase...
September 2016: Giornale Italiano di Cardiologia
https://www.readbyqxmd.com/read/27831499/association-of-traditional-cardiovascular-risk-factors-with-venous-thromboembolism-an-individual-participant-data-meta-analysis-of-prospective-studies
#6
Bakhtawar K Mahmoodi, Mary Cushman, Inger Anne Næss, Matthew A Allison, Willem Jan Bos, Sigrid K Brækkan, Suzanne Cannegieter, Ron T Gansevoort, Philimon N Gona, Jens Hammerstrøm, John-Bjarne Hansen, Susan Heckbert, Anders G Holst, Susan G Lakoski, Pamela L Lutsey, JoAnn E Manson, Lisa W Martin, Kunihiro Matsushita, Karina Meijer, Kim Overvad, Eva B Prescott, Marja K Puurunen, Jacques Rossouw, Yingying Sang, Marianne T Severinsen, Jur M Ten Berg, Aaron R Folsom, Neil A Zakai
BACKGROUND: -There is much controversy surrounding the association of traditional cardiovascular disease (CVD) risk factors with venous thromboembolism (VTE). METHODS: - We performed an individual level random-effect meta-analysis including 9 prospective studies with measured baseline CVD risk factors and validated VTE events. Definitions were harmonized across studies. Traditional CVD risk factors were modeled categorically, as well as continuously using restricted cubic splines...
November 9, 2016: Circulation
https://www.readbyqxmd.com/read/27792654/association-between-life-s-simple-7-and-noncardiovascular-disease-the-multi-ethnic-study-of-atherosclerosis
#7
Oluseye Ogunmoroti, Norrina B Allen, Mary Cushman, Erin D Michos, Tatjana Rundek, Jamal S Rana, Ron Blankstein, Roger S Blumenthal, Michael J Blaha, Emir Veledar, Khurram Nasir
BACKGROUND: The American Heart Association introduced the Life's Simple 7 (LS7) metrics to assess and promote cardiovascular health. We examined the association between the LS7 metrics and noncardiovascular disease. METHODS AND RESULTS: We studied 6506 men and women aged between 45 and 84 years, enrolled in the Multi-Ethnic Study of Atherosclerosis. Median follow-up time was 10.2 years. Each component of the LS7 metrics (smoking, body mass index, physical activity, diet, total cholesterol, blood pressure, and blood glucose) was assigned points, 0 indicates "poor" category; 1, "intermediate," and 2, "ideal...
October 20, 2016: Journal of the American Heart Association
https://www.readbyqxmd.com/read/27755234/expression-of-tissue-factor-in-epithelial-ovarian-carcinoma-is-involved-in-the-development-of-venous-thromboembolism
#8
Manabu Sakurai, Koji Matsumoto, Masahiko Gosho, Akiko Sakata, Yoshihiko Hosokawa, Yuri Tenjimbayashi, Takashi Katoh, Ayumi Shikama, Haruna Komiya, Hiroo Michikami, Nobutaka Tasaka, Azusa Akiyama-Abe, Sari Nakao, Hiroyuki Ochi, Mamiko Onuki, Takeo Minaguchi, Hiroyuki Yoshikawa, Toyomi Satoh
OBJECTIVES: Our 2007 study of 32 patients with ovarian cancer reported the possible involvement of tissue factor (TF) in the development of venous thromboembolism (VTE) before treatment, especially in clear cell carcinoma (CCC). This follow-up study further investigated this possibility in a larger cohort. METHODS: We investigated the intensity of TF expression (ITFE) and other variables for associations with VTE using univariate and multivariate analyses in 128 patients with epithelial ovarian cancer initially treated between November 2004 and December 2010, none of whom had received neoadjuvant chemotherapy...
October 17, 2016: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/27740860/management-of-idiopathic-venous-thromboembolism
#9
Benilde Cosmi
Idiopathic or unprovoked venous thromboembolism is an event occurring in the absence of any apparent provoking or triggering environmental risk factors, such as surgery, trauma, and immobilization. Areas covered: Unprovoked VTE can be associated with occult cancer, but only limited, and not extensive cancer screening, may be warranted, as the rate of occult cancer is low in such patients. Routine thrombophilia testing is not currently recommended as it does not influence the management of the disease. The duration of anticoagulation for unprovoked VTE after the first three months is still debated as the disease tends to recur regardless of treatment duration...
December 2016: Expert Review of Cardiovascular Therapy
https://www.readbyqxmd.com/read/27727456/time-dependent-risk-and-predictors-of-venous-thromboembolism-in-breast-cancer-patients-a-population-based-cohort-study
#10
Judith S Brand, Elham Hedayati, Nirmala Bhoo-Pathy, Jonas Bergh, Per Hall, Keith Humphreys, Jonas F Ludvigsson, Kamila Czene
BACKGROUND: Venous thromboembolism (VTE) is a serious complication of cancer and its treatment. The current study assessed the risk and clinical predictors of VTE in breast cancer patients by time since diagnosis. METHODS: This Swedish population-based study included 8338 breast cancer patients diagnosed from 2001 to 2008 in the Stockholm-Gotland region with complete follow-up until 2012. Their incidence of VTE was compared with the incidence among 39,013 age-matched reference individuals from the general population...
October 11, 2016: Cancer
https://www.readbyqxmd.com/read/27696084/safe-and-effective-use-of-rivaroxaban-for-treatment-of-cancer-associated-venous-thromboembolic-disease-a-prospective-cohort-study
#11
Simon Mantha, Eva Laube, Yimei Miao, Debra M Sarasohn, Rekha Parameswaran, Samantha Stefanik, Gagandeep Brar, Patrick Samedy, Jonathan Wills, Stephen Harnicar, Gerald A Soff
Low-molecular weight heparin (LMWH) has been the standard of care for treatment of venous thromboembolism (VTE) in patients with cancer. Rivaroxaban was approved in 2012 for the treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT), but no prior studies have been reported specifically evaluating the efficacy and safety of rivaroxaban for cancer-associated thrombosis (CAT). Under a Quality Assessment Initiative (QAI), we established a Clinical Pathway to guide rivaroxaban use for CAT and now report a validation analysis of our first 200 patients...
September 30, 2016: Journal of Thrombosis and Thrombolysis
https://www.readbyqxmd.com/read/27682430/-iron-deficiency-thrombocytosis-and-thromboembolism
#12
Rayko Evstatiev
Iron deficiency, the most common nutritional deficiency worldwide, is often associated with reactive thrombocytosis. Although secondary thrombocytosis is commonly considered to be harmless, there is accumulating evidence that elevated platelet counts, especially in the setting of iron deficiency, can lead to an increased thromboembolic risk in both arterial and venous systems. Here we present the mechanisms of iron deficiency-induced thrombocytosis and summarize its clinical consequences especially in patients with inflammatory bowel diseases, chronic kidney disease or cancer...
October 2016: Wiener Medizinische Wochenschrift
https://www.readbyqxmd.com/read/27637910/the-khorana-score-in-predicting-venous-thromboembolism-for-patients-with-metastatic-urothelial-carcinoma-and-variant-histology-treated-with-chemotherapy
#13
Jorge D Ramos, Martin F Casey, Aristotelis Bamias, Ugo De Giorgi, Joaquim Bellmunt, Lauren C Harshman, Sylvain Ladoire, Yu-Ning Wong, Ajjai S Alva, Jonathan E Rosenberg, Matthew D Galsky, Evan Y Yu
BACKGROUND: The Khorana score is a predictive risk model for venous thromboembolism (VTE) in patients with cancer planning to receive chemotherapy. Urothelial carcinoma and variant histologies (UC/VH) were underrepresented in the model. We sought to evaluate whether the Khorana score predicts for VTE in a retrospective multinational data set of patients with metastatic UC/VH. METHODS: Patients diagnosed with metastatic UC/VH who received chemotherapy were eligible...
September 16, 2016: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/27637548/laboratory-assessment-of-the-anticoagulant-activity-of-direct-oral-anticoagulants-doacs-a-systematic-review
#14
Bethany T Samuelson, Adam Cuker, Deborah M Siegal, Mark Crowther, David A Garcia
BACKGROUND: The direct oral anticoagulants (DOACs) are the treatment of choice for most patients with atrial fibrillation and/or non-cancer associated venous thromboembolic disease. While routine monitoring of these agents is not required, assessment of anticoagulant effect may be desirable in special situations. The objective of this study was to systematically review and summarize current evidence regarding laboratory assessment of the anticoagulant effects of dabigatran, rivaroxaban, apixaban and edoxaban...
September 13, 2016: Chest
https://www.readbyqxmd.com/read/27623680/exploring-unmet-needs-in-venous-and-arterial-thromboembolism-with-rivaroxaban
#15
Riccardo Cappato, Robert Welsh
The vast clinical research programme for the direct, oral factor Xa inhibitor rivaroxaban has generated a wealth of data since the first rivaroxaban approval in 2008 for the prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery. While rivaroxaban is widely used across a spectrum of seven indications, there is continuous commitment to investigating its wider benefits in new indications and attempts to refine current evidence. Key data from recently completed randomised controlled trials (RCTs) have shown that rivaroxaban is a feasible anticoagulation option for patients with non-valvular atrial fibrillation (NVAF) undergoing cardioversion or catheter ablation...
September 28, 2016: Thrombosis and Haemostasis
https://www.readbyqxmd.com/read/27599614/idiopathic-pulmonary-fibrosis-effects-and-optimal-management-of-comorbidities
#16
Christopher S King, Steven D Nathan
Despite the development of pharmacological therapies that are effective in slowing the progression of idiopathic pulmonary fibrosis (IPF), it remains a debilitating and lethal condition. In addition to the adverse effects caused by pulmonary fibrosis, most patients with IPF have associated comorbid conditions, which might negatively affect functional status, quality of life, and survival. Comorbid conditions can be pulmonary or extrapulmonary. Pulmonary comorbidities include pulmonary hypertension, emphysema, and lung cancer, while non-pulmonary conditions include venous thromboembolism, coronary artery disease, congestive heart failure, sleep-disordered breathing, gastro-oesophageal reflux disease, and anxiety or depression...
September 2, 2016: Lancet Respiratory Medicine
https://www.readbyqxmd.com/read/27586589/platelet-count-is-associated-with-cardiovascular-disease-cancer-and-mortality-a-population-based-cohort-study
#17
P J Vinholt, A M Hvas, H Frederiksen, L Bathum, M K Jørgensen, M Nybo
INTRODUCTION: Platelet count is used to determine bleeding risk and monitoring thrombopoiesis. While abnormal platelet counts are associated with mortality and morbidity, it is unclear whether it also apply to platelet counts within reference range. We investigated the relationship between platelet count (100-450×10(9)/L) and mortality, development of future cardiovascular disease (myocardial infarction, ischaemic stroke, or peripheral vascular disease), venous thromboembolism, bleeding or cancer in the general population...
August 20, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/27582024/association-of-nonalcoholic-fatty-liver-disease-and-venous-thromboembolism-in-women-with-endometrial-cancer
#18
Aida Moeini, Hiroko Machida, Tsuyoshi Takiuchi, Erin A Blake, Marianne S Hom, Toshio Miki, Osamu Matsuo, Koji Matsuo
OBJECTIVE: Recent studies have demonstrated that surgical menopause results in a significantly increased risk of nonalcoholic fatty liver disease (NAFLD) in women with endometrial cancer. In addition, venous thromboembolism (VTE) is known to be one of the major prognostic factors for decreased survival in endometrial cancer. Given the fact that coagulation factors are produced in the liver, the correlation between NAFLD and VTE was examined in endometrial cancer. METHODS: A retrospective study was conducted to examine patients with endometrial cancer who underwent surgical staging including oophorectomy between 2000 and 2013 (n = 714)...
August 31, 2016: Clinical and Applied Thrombosis/hemostasis
https://www.readbyqxmd.com/read/27485842/-long-term-treatment-of-venous-thromboembolism-in-patients-with-cancer
#19
Jan Šmrha, Petr Kessler, Hynek Poul, Michaela Harudová
BACKGROUND: The treatment with low-molecular-weight heparin (LMWH) is recommended for patients with cancer associated thrombosis (CAT) during the first 6 months; the initial therapeutic dose can be reduced to 60-75 % after one month. The therapy should be reevaluated after 6 month and subsequent therapy using LMWH or warfarin is recommended indefinitely, unless the cancer is resolved or any major contraindications arise. AIMS: To analyze the usage of various treatment modalities in CAT patients after the initial 6 month period according to the course of cancer...
2016: Vnitr̆ní Lékar̆ství
https://www.readbyqxmd.com/read/27477669/anticoagulation-is-associated-with-decreased-inferior-vena-cava-filter-related-complications-in-metastatic-carcinoma-patients
#20
Syed S Mahmood, Farhad Abtahian, Annemarie E Fogerty, Philip Cefalo, Cheryl MacKay, Michael R Jaff, Ido Weinberg
BACKGROUND: Patients with metastatic carcinoma and venous thromboembolism commonly have contraindications to anticoagulation that prompts use of retrievable inferior vena cava filters. OBJECTIVES: The aim of this study was to compare the pattern of inferior vena cava filter use, anticoagulation management and development of inferior vena cava filter related complications in patients with localized versus metastatic carcinoma. METHODS: We conducted a retrospective cohort study of inferior vena cava filter use at a tertiary referral hospital between January 1, 2009 and December 31, 2011...
July 28, 2016: American Journal of Medicine
keyword
keyword
66622
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"